EVOQ Therapeutics
3 known investors
Find your way into EVOQ Therapeutics
EVOQ Therapeutics develops immunotherapies targeting autoimmune diseases by using proprietary NanoDisc technology to restore immune tolerance. The company focuses on treating conditions like Type 1 Diabetes, Multiple Sclerosis, and Lupus through novel therapeutic approaches.
Investors · 3
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $761.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $287.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does EVOQ Therapeutics do?
- EVOQ Therapeutics develops immunotherapies targeting autoimmune diseases by using proprietary NanoDisc technology to restore immune tolerance. The company focuses on treating conditions like Type 1 Diabetes, Multiple Sclerosis, and Lupus through novel therapeutic approaches.
- Who are EVOQ Therapeutics's investors?
- EVOQ Therapeutics's investors include ID Ventures, Invest Michigan, Michigan Rise.